|
New Targeted Therapy for Solid Tumors and Lymphomas
Untitled Document
Name of the Trial
Phase I Study of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG)
in Patients with Advanced Solid Tumors or Lymphoma (NCI-04-C-0218). See the
protocol summary.
Principal Investigator
Dr. Martin Gutierrez, NCI's Center for Cancer Research.
Why Is This Trial Important?
Heat shock proteins (HSPs) are found in every cell of the body. HSPs help cells
survive stressful conditions (including heat, cold, nutrient starvation, and
oxygen deprivation) by protecting other proteins. Under non-stressful conditions,
HSPs help proteins achieve and maintain their proper shape. Researchers at NCI
are investigating a particular HSP, called HSP-90, as a target for cancer therapy.
Many of the proteins implicated in cancer development need HSP-90 to help them
achieve their correct functional shape and cellular location.
In this trial, researchers are studying 17-DMAG, an HSP-90 inhibitor developed
by the NCI, to see if it can help prevent cancer cells from growing in patients
with solid tumors or lymphomas. The trial will also be used to determine the
maximum dose of 17-DMAG that can be given to patients and examine what side
effects the drug may cause.
"Preclinical research results suggest that inhibiting HSP-90 will
alter
many of the protein pathways in tumor cells and may result in tumor cell death,"
said Dr. Gutierrez. "This is the first test of 17-DMAG in humans, and so
far, the drug has been well tolerated.
"We think that 17-DMAG's mode of action may represent an important new
approach in the treatment of many types of cancer."
Contact Information
This clinical trial is no longer accepting new patients. To locate other clinical
trials for solid tumors or lymphoma, search the NCI
database of clinical trials or call the NCI Clinical Trials Referral Office at
1-888-NCI-1937. The
call is toll free and confidential.
 Back to Top |
